کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8430174 | 1546230 | 2018 | 24 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Rela
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
Allogeneic hematopoietic stem cell transplantation (SCT) represents a potential curative strategy for patients with Hodgkin lymphoma (HL) relapsing after autologous SCT (ASCT), but the incidence of disease relapse is still high. We performed a retrospective study on 64 patients with HL relapsing after ASCT to compare outcomes after HLA-identical SCT (HLAid-SCT; nâ=â34) and haploidentical SCT with post-transplantation cyclophosphamide (PT-Cy) (Haplo-SCT; nâ=â30). All patients engrafted, with a significantly shorter median time for neutrophil and platelet engraftment after HLAid compared with Haplo-SCT (14 days versus 19 days and 11 days versus 23 days, respectively; Pâ<â.005). With a median follow-up of 47 months, 3-year overall survival (OS), 3 -year progression-free survival (PFS), and 1-year nonrelapse mortality (NRM) were 53%, 44% and 17%, respectively. Recipients of Haplo-SCT were less likely to experience disease relapse (3-year cumulative incidence of relapse, 13% versus 62%; Pâ=â.0001) and chronic graft- versus-host disease (GVHD; 3% versus 32%; Pâ=â.003), resulting in improved PFS (60% versus 29%; Pâ=â.04) and GVHD-free/relapse-free survival (47% versus 17%; Pâ=â.06). The 3-year OS did not differ between the 2 groups (56% versus 54%; Pânot significant), and NRM was higher after Haplo-SCT, but the difference did not reach statistical significance (26% versus 9%; Pâ=â.09). On multivariate Cox regression analysis, receipt of Haplo-SCT (hazard ratio [HR], .17; Pâ=â.02) and achieving optimal disease control (complete remission before SCT: HR, .6; Pâ<â.0001) were the only independent variables associated with a reduced risk of disease relapse. Haplo-SCT is a valid option for patients with HL relapsing after ASCT, with a reduced incidence of relapse compared with HLAid SCT.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Biology of Blood and Marrow Transplantation - Volume 24, Issue 3, March 2018, Pages 627-632
Journal: Biology of Blood and Marrow Transplantation - Volume 24, Issue 3, March 2018, Pages 627-632
نویسندگان
Jacopo Mariotti, Raynier Devillier, Stefania Bramanti, Barbara Sarina, Sabine Furst, Angela Granata, Catherine Faucher, Samia Harbi, Lucio Morabito, Christian Chabannon, Carmelo Carlo-Stella, Reda Bouabdallah, Armando Santoro, Didier Blaise,